Drug Price Transparency for Medicare Patients Act of 2019

Summary

Drug Price Transparency for Medicare Patients Act of 2019 This bill provides statutory authority for the Centers for Medicare & Medicaid Services rule titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," published on May 10, 2019. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule takes effect July 9, 2019.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 18 June 2019

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 18 June 2019

   Introduced

   Introduced in House

   Source: IntroReferral

3. 18 June 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 19 June 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 18 June 2019 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 18 June 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 18 June 2019

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 18 June 2019

  Open at official source

Sponsors

• Francis Rooney · R · Sponsor
• Daniel Lipinski · D · Cosponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

No cross-record relationships stored yet.